Učitavanje...
A review of omalizumab for the management of severe asthma
Despite the expansion of the understanding in asthma pathophysiology and the continual advances in disease management, a small subgroup of patients remain partially controlled or refractory to standard treatments. Upon the identification of immunoglobulin E and other inflammatory mediators, investig...
Spremljeno u:
| Izdano u: | Drug Des Devel Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4970638/ https://ncbi.nlm.nih.gov/pubmed/27528798 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S112208 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|